Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249967 | 0.81 | CA12 (0.49) | — | |
| SCHEMBL564715 | 0.79 | ALDH1A1 (0.40) | — | |
| SCHEMBL30751778 | 0.78 | XDH (0.45) | XDH | |
| SCHEMBL29530667 | 0.78 | ALDH1A1 (0.39) | XDH | |
| SCHEMBL365309 | 0.78 | XDH (0.45) | XDH | |
| SCHEMBL20364818 | 0.77 | ALDH1A1 (0.38) | XDH | |
| SCHEMBL1667585 | 0.76 | HTR1A (0.56) | XDHSLC22A12 | |
| SCHEMBL4069875 | 0.76 | ALDH1A1 (0.40) | — | |
| SCHEMBL564720 | 0.75 | CYP1A2 (0.56) | SLC22A12 | |
| SCHEMBL29530749 | 0.75 | CYP1A2 (0.56) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499570-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-9145429-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-8716478-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | XDH 2793/4885SLC22A12 1307/4885 |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | XDH 2793/4885SLC22A12 1307/4885 |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | XDH 2793/4885SLC22A12 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.